| 000 | 01716 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517133254.0 | ||
| 264 | 0 | _c20171122 | |
| 008 | 201711s 0 0 eng d | ||
| 022 | _a2326-6074 | ||
| 024 | 7 |
_a10.1158/2326-6066.CIR-16-0288 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMelief, Sara M | |
| 245 | 0 | 0 |
_aLong-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature. _h[electronic resource] |
| 260 |
_bCancer immunology research _c02 2017 |
||
| 300 |
_a170-179 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aBiomarkers |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGalectins _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunity |
| 650 | 0 | 4 | _aImmunotherapy, Adoptive |
| 650 | 0 | 4 |
_aMacrophages _ximmunology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _ximmunology |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aT-Lymphocyte Subsets _ximmunology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aVisconti, Valeria V | |
| 700 | 1 | _aVisser, Marten | |
| 700 | 1 | _avan Diepen, Merel | |
| 700 | 1 | _aKapiteijn, Ellen H W | |
| 700 | 1 | _avan den Berg, Joost H | |
| 700 | 1 | _aHaanen, John B A G | |
| 700 | 1 | _aSmit, Vincent T H B M | |
| 700 | 1 | _aOosting, Jan | |
| 700 | 1 | _avan der Burg, Sjoerd H | |
| 700 | 1 | _aVerdegaal, Els M E | |
| 773 | 0 |
_tCancer immunology research _gvol. 5 _gno. 2 _gp. 170-179 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/2326-6066.CIR-16-0288 _zAvailable from publisher's website |
| 999 |
_c26771473 _d26771473 |
||